On April 2, Gelonghui (09989.HK) announced that Exarane (one of the Group's leading drugs for enoxaparin sodium injections) produced by its wholly-owned subsidiary Shenzhen Tiandao Pharmaceutical Co., Ltd. has been approved for marketing by the Food and Drug Administration of Thailand.
The announcement stated that with this approval, the ennoxaparin sodium formulation representing the Group Hypree will be sold in the Thai market, which will further increase the global market share of the Group's enoxaparin sodium preparations. The Group believes that this approval is another important achievement in implementing the international layout of the Group's pharmaceutical business, once again proving the Group's ability to enter overseas markets. In the future, the Group will continue to make efforts to accelerate the Group's global market expansion process and sales channel construction, and pave the way for further strengthening overseas market development in the future.